LCTX
Lineage Cell Therapeutics Inc
0.9303$
+2.9%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +67.6% | -30.8% | -2.5% | +168.4% | -24.1% | -47.6% | +84.1% | +33.1% | +79.5% | -73.9% | -38.0% | – | |
| – | +155.0% | -36.7% | -83.9% | -13.6% | +305.3% | -76.6% | +8.3% | -87.2% | +1,220.0% | +184.8% | -0.5% | – | |
| – | +53.9% | -29.3% | +16.5% | +174.3% | -27.5% | -46.0% | +85.9% | +34.8% | +78.0% | -76.5% | -42.6% | – | |
| – | +3.6% | -22.9% | -4.0% | +10.6% | +7.9% | -9.0% | -0.3% | +5.3% | +151.8% | -48.6% | +12.8% | – | |
| – | +6.1% | +16.5% | -12.7% | +1.1% | -0.2% | +10.4% | -6.1% | -8.1% | +15.8% | +4.8% | +2.6% | – | |
| – | +3.0% | -2.3% | -7.7% | +4.8% | +3.2% | +1.9% | +182.3% | -66.8% | +75.4% | -30.3% | +7.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -126.2% | – | – | -69.7% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | -665.5% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.